Kennedy R. Lees
University of Glasgow
467 Papers
3.9K Citations
Kennedy R. Lees is an academic researcher from University of Glasgow. The author has contributed to research in topics: Stroke & Medicine. The author has an hindex of 86, co-authored 455 publications. Previous affiliations of Kennedy R. Lees include Ludwig Maximilian University of Munich & Cedars-Sinai Medical Center.
Chat about Author
Papers
Allopurinol and Nitric Oxide Activity in the Cerebral Circulation of Those With Diabetes A randomized trial
Jesse Dawson,Terry J Quinn,Craig Harrow,Kennedy R. Lees,Christopher J. Weir,Stephen J. Cleland,Matthew Walters +6 more
TL;DR: Xanthine oxidase inhibition with allopurinol appears to improve cerebral NO bioavailability, as evidenced by a greater response to infusion of l-NMMA.
34
Targeting Neuroprotection Clinical Trials to Ischemic Stroke Patients With Potential to Benefit From Therapy
TL;DR: Targeting patients with potential to benefit enables a substantial sample size reduction without compromising statistical power or duration of recruitment, and informed use of prognostic data available acutely would help in identifying effective neuroprotective treatments.
34
Results of Membrane-activated Chelator Stroke Intervention Randomized Trial of DP-b99 in Acute Ischemic Stroke
Kennedy R. Lees,Natan M. Bornstein,Hans-Christoph Diener,Philip B. Gorelick,Gilad Rosenberg,Ashfaq Shuaib +5 more
TL;DR: DP-b99 shows no evidence of efficacy in treating human ischemic stroke, despite encouraging preclinical and phase II trial data.
34
Epidemiological aspects of referral to TIA clinics in Glasgow
S Murray,Khurram Bashir,Kennedy R. Lees,Keith W. Muir,C MacAlpine,Margaret Roberts,Peter Langhorne +6 more
TL;DR: A retrospective cohort study was carried out of new referrals to transient ischaemic attack (TIA) clinics in Glasgow to assess the odds ratios for TIA, minor stroke or amaurosis fugax of both cardiovascular risk factors and clinical features.
33
Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers.
TL;DR: Aptiganel HCl causes elevation of blood pressure and is associated with central nervous system symptoms and signs similar to other noncompetitive NMDA antagonists and is well tolerated by healthy males.
33